CERS CERUS CORP

NEUTRAL Impact: 3/10 DEFA14A
Horizon weeks Filed Apr 22, 2026 Processed 1mo ago SEC 0001020214-26-000012
Proxy solicitation materials
Latest settled — T+20d ⚠ clustered
CERS ▲ +39.18% at T+20d
NEUTRAL call ✓ call won +39.18% · α vs SPY +36.01% · entry $1.94 → $2.70
Next anchor: T+60d in 5w
Currently $2.56 · +31.96% from $1.94 entry
Entry anchored
Apr 22, 12:01 PM ET
via Databento tick
T+1d
-2.06%
call -2.06% · α -1.67%
$1.90
settled 7w ago
T+5d
-0.52%
call -0.52% · α -0.57%
$1.93
settled 6w ago
T+20d
+39.18%
call +39.18% · α +36.01%
$2.70
settled 24d ago
T+60d
call — · α —
in 5w

Price Chart

Loading chart...

Executive Summary

Cerus Corporation filed a definitive proxy statement (DEFA14A) for its 2026 Annual Meeting, proposing the election of two directors, an increase in shares for its equity incentive plan, advisory approval of executive compensation, and ratification of its auditor. This filing follows a recent 8-K filing announcing a new severance plan for executives, suggesting board-level changes are materializing.

Actionable Insight

Monitor the shareholder vote results for the equity incentive plan amendment, as the 10 million new shares represent significant potential dilution. The recent severance plan adoption suggests internal changes, but the proxy itself is routine.

Key Facts

  • Proposes election of two nominees for director: William M. Greenman and Ann Lucena.
  • Seeks approval to increase shares in the 2024 Equity Incentive Plan by 10 million.
  • Requests advisory approval of named executive officer compensation.
  • Seeks ratification of Ernst & Young LLP as the independent auditor.
  • Follows a recent 8-K filing (Items: 5.02) that established a new severance plan for certain executive officers.

Financial Impact

The plan amendment would authorize 10 million additional shares for issuance.

dilution

Risk Factors

  • Potential shareholder opposition to the significant increase in shares for the equity incentive plan.
  • The new severance plan could signal executive turnover or strategic shifts.

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001020214-26-000012
Document: 0001020214-26-000012-index-headers.html0001020214-26-000012
Document: 0001020214-26-000012-index.html0001020214-26-000012
Document: 0001020214-26-000012.txt0001020214-26-000012
6 reports for CERS
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for CERS — sortable, filterable
Type Now
Apr 30, 2026
6w ago
8-K
BULLISH ★ 7/10
$2.72 $2.84▲ +4.41%▼ −0.87%$2.56 (−5.88%)
Apr 22, 2026
7w ago
DEFA14A
NEUTRAL ★ 3/10
$1.94 $2.70▲ +39.18%▲ +36.01%$2.56 (+31.96%)
Apr 21, 2026
7w ago
8-K
NEUTRAL ★ 3/10
$1.94 $2.70▲ +39.18%▲ +36.01%$2.56 (+31.96%)
Mar 6, 2026
14w ago
Insider Cluster
BEARISH ★ 6/10
$1.93 $1.85▲ +4.15%▲ +2.10%$2.56 (−32.64%)
Mar 6, 2026
14w ago
Insider Cluster
NEUTRAL ★ 3/10
$1.93 $1.85▼ −4.15%▼ −2.10%$2.56 (+32.64%)
Mar 5, 2026
14w ago
Insider Cluster
NEUTRAL ★ 4/10
$2.04 $1.86▼ −8.82%▼ −5.03%$2.56 (+25.49%)
Showing 6 of 6

US Market Status

Market Closed — Opens Mon (48h 50m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access